Global Health Expert to Lead Public Sector Initiatives at Medical Nutrition Company PanTheryx

25-year veteran Dr. Mark Grabowsky will build partnerships with nonprofits, nongovernmental organizations and ministries of health to address diarrhea in children.

BOULDER, Colorado – (BUSINESS WIRE) – Dec. 14, 2015 – PanTheryx Inc., a global medical nutrition company based in Boulder, Colorado, has hired Dr. Mark Grabowsky to direct the company’s expanding relationships with U.S. health agencies, foreign ministries of health and nongovernment organizations. As vice president of public initiatives, Grabowsky now leads PanTheryx’s public health outreach to increase access to the company’s breakthrough nutritional intervention for diarrhea.

An expert on disease prevention and child health, Grabowsky brings to PanTheryx over 25 years of experience at the forefront of many of the most difficult global health challenges including efforts to reduce measles and malaria deaths in developing countries and advance HIV-prevention strategies. As chief operating officer, he most recently directed strategic partnerships to help finance the United Nations’ Millennium Development Goals. Prior to that, he led the coordination of federal agencies to implement the National Vaccine Plan for the Department of Health and Human Services. Grabowsky has also held senior level posts at the World Health Organization, Centers for Disease Control, National Institute of Health, American Red Cross and the Canadian International Development Agency.

In his new role with PanTheryx, Grabowsky oversees relationships with ministries of health, public health care programs and nongovernmental organizations to ensure that the poorest and hardest to reach families globally will have access to the company’s flagship product, DiaResQ^®. In support of these efforts, Grabowsky oversees PanTheryx’ clinical trials.

“As the new vice president of public sector initiatives, Dr. Grabowsky brings a wealth of global health experience, and strategic relationships,” said Mark A. Braman, president and CEO of PanTheryx. “He has been a leader in applying innovative solutions to alleviate the most pressing global health concerns, including measles, polio and malaria. His extensive knowledge and practical experience leading disease control partnerships will be invaluable in helping PanTheryx fulfill its mission of reducing mortality and improving the quality of life for children and their families worldwide.”

“I’m thrilled about the opportunity to join PanTheryx and help address one of today’s most important global health issues,” Dr. Grabowsky said. “PanTheryx’s unique, non-drug, nutritional approach represents a complete paradigm shift in how diarrhea is addressed in children.”

Dr. Grabowsky holds a medical degree from Virginia Commonwealth University and a master’s in public health from Johns Hopkins School of Public Health.

This announcement follows several recent milestones for the company. PanTheryx’s DiaResQ^® was selected in the inaugural report of the Innovation Countdown 2030, Reimagining Global Health as one of the 30 leading healthcare innovations with great promise to transform global health by 2030 and to help accelerate progress toward new health targets proposed in the United Nations Sustainable Development Goals.

PanTheryx recently announced a multi-country supply and licensing agreement with Dr. Reddy’s Laboratories Ltd. (NYSE: RDY), to market and distribute the company’s product in India, Nepal, Russia, Myanmar, Vietnam, Ukraine, Sri Lanka, Kazakhstan, Belarus, Jamaica, and select Latin American markets. In the United States, PanTheryx launched Traveler’s DiaResQ^® in select Passport Health clinics nationwide.

About PanTheryx:
Founded in 2007, PanTheryx is a global medical nutrition company based in Boulder, Colorado, and is dedicated to improving global health and quality of life through innovative life science. Utilizing its broad-based proprietary technology platform, PanTheryx is focused on the research, development and commercialization of medical nutrition products targeting the gastrointestinal microbiome. The company’s lead product addresses acute infectious diarrhea, a leading cause of death worldwide among children under the age of five. For more information, log on to: www.pantheryx.com andwww.diaresq.com.